OBJECTIVES: Prothrombin complex concentrates (PCCs) are sometimes used as 'off label' for excessive bleeding after cardiopulmonary bypass (CPB). The main objective of this study was to retrospectively evaluate the clinical and biological efficacy of PCC in this setting. METHODS: We reviewed the charts of all patients who had undergone cardiac surgery under CPB in our institution for 2 years. Patients treated for active bleeding with haemostatic therapy were identified. Chest tube blood loss was quantified postoperatively in the first 24 h. Coagulation parameters were recorded at intensive care unit admission and in the patient's first 24 h. Thromboembolic complications were also ascertained. RESULTS: Seventy-seven patients out of the 677 studied (11.4%) were included: PCC was solely administered in 24 patients (group I), fresh frozen plasma in 26 (group II) and both in 27 (group III). The mean dose of PCC was 10.0 UI/kg ± 3.5 for group I vs 14.1 UI/kg ± 11.2 for group III (P = 0.09). Initial blood loss in the first hour was different between the three groups (P = 0.05): 224 ± 131 ml for group I, 369 ± 296 ml for group II and 434 ± 398 ml for group III. Only group I vs group III presented a significant difference (P = 0.02). Variations of blood loss over time were no different according to the treatment groups (P = 0.12). Reductions in blood loss expressed in percentage showed no difference between the three groups after 2 h: 54.5% (68.6-30.8) for group I; 45.0% (81.6-22.2) for group II; 57.6 (76.0-2.1) for group III; (P = 0.89). Re-exploration for bleeding involved 1 patient in group I (4%), 2 in group II (8%) and 10 in group III (37%) (P = 0.002). Except for fibrinogen, variations of prothrombin time, activated partial thromboplastin time and platelets with time were not different according to the treatment groups. Cerebral infarction occurred in one patient in group II. CONCLUSIONS: Administration of low-dose of PCC significantly decreased postoperative bleeding after CPB.
OBJECTIVES: Prothrombin complex concentrates (PCCs) are sometimes used as 'off label' for excessive bleeding after cardiopulmonary bypass (CPB). The main objective of this study was to retrospectively evaluate the clinical and biological efficacy of PCC in this setting. METHODS: We reviewed the charts of all patients who had undergone cardiac surgery under CPB in our institution for 2 years. Patients treated for active bleeding with haemostatic therapy were identified. Chest tube blood loss was quantified postoperatively in the first 24 h. Coagulation parameters were recorded at intensive care unit admission and in the patient's first 24 h. Thromboembolic complications were also ascertained. RESULTS: Seventy-seven patients out of the 677 studied (11.4%) were included: PCC was solely administered in 24 patients (group I), fresh frozen plasma in 26 (group II) and both in 27 (group III). The mean dose of PCC was 10.0 UI/kg ± 3.5 for group I vs 14.1 UI/kg ± 11.2 for group III (P = 0.09). Initial blood loss in the first hour was different between the three groups (P = 0.05): 224 ± 131 ml for group I, 369 ± 296 ml for group II and 434 ± 398 ml for group III. Only group I vs group III presented a significant difference (P = 0.02). Variations of blood loss over time were no different according to the treatment groups (P = 0.12). Reductions in blood loss expressed in percentage showed no difference between the three groups after 2 h: 54.5% (68.6-30.8) for group I; 45.0% (81.6-22.2) for group II; 57.6 (76.0-2.1) for group III; (P = 0.89). Re-exploration for bleeding involved 1 patient in group I (4%), 2 in group II (8%) and 10 in group III (37%) (P = 0.002). Except for fibrinogen, variations of prothrombin time, activated partial thromboplastin time and platelets with time were not different according to the treatment groups. Cerebral infarction occurred in one patient in group II. CONCLUSIONS: Administration of low-dose of PCC significantly decreased postoperative bleeding after CPB.
Authors: M Levi; D Fries; H Gombotz; Ph van der Linden; B Nascimento; J L Callum; S Bélisle; S Rizoli; J-F Hardy; P I Johansson; C M Samama; O Grottke; R Rossaint; C P Henny; J C Goslings; O M Theusinger; D R Spahn; M T Ganter; J R Hess; R P Dutton; T M Scalea; J H Levy; P C Spinella; S Panzer; H W Reesink Journal: Vox Sang Date: 2011-08 Impact factor: 2.144
Authors: L J Dacey; J J Munoz; Y R Baribeau; E R Johnson; S J Lahey; B J Leavitt; R D Quinn; W C Nugent; J D Birkmeyer; G T O'Connor Journal: Arch Surg Date: 1998-04
Authors: Klaus Görlinger; Daniel Dirkmann; Alexander A Hanke; Markus Kamler; Eva Kottenberg; Matthias Thielmann; Heinz Jakob; Jürgen Peters Journal: Anesthesiology Date: 2011-12 Impact factor: 7.892
Authors: G A Nuttall; W C Oliver; P J Santrach; S Bryant; J A Dearani; H V Schaff; M H Ereth Journal: Anesthesiology Date: 2001-05 Impact factor: 7.892
Authors: T Staudinger; M Frass; C Rintelen; P Quehenberger; O Wagner; B Stoiser; G J Locker; K Laczika; S Knapp; H Watzke Journal: Intensive Care Med Date: 1999-10 Impact factor: 17.440
Authors: Nazish K Hashmi; Kamrouz Ghadimi; Amudan J Srinivasan; Yi-Ju Li; Robert D Raiff; Jeffrey G Gaca; Adam G Root; Yaron D Barac; Thomas L Ortel; Jerrold H Levy; Ian J Welsby Journal: Vox Sang Date: 2019-04-02 Impact factor: 2.144
Authors: J Trent Magruder; Stephen Belmustakov; Rika Ohkuma; Sarah Collica; Joshua C Grimm; Todd Crawford; John V Conte; William A Baumgartner; Ashish S Shah; Glenn R Whitman Journal: Gen Thorac Cardiovasc Surg Date: 2016-09-20
Authors: Charles L Percy; Rudolf Hartmann; Rhidian M Jones; Subramaniam Balachandran; Dheeraj Mehta; Michael Dockal; Friedrich Scheiflinger; Valerie B O'Donnell; Judith E Hall; Peter W Collins Journal: Blood Coagul Fibrinolysis Date: 2015-06 Impact factor: 1.276